Brooke Nickel

Aug 10, 2024 | bmjopen.bmj.com | James Bullen |Brooke Nickel |Kirsten J McCaffery |Timothy J. Wilt

Methods and analysisTwo separate online randomised studies of Australian residents will be run for men and for women. For both studies, participants will be randomised to receive one of three hypothetical scenarios about the diagnosis of a low-risk prostate cancer received by themselves or their partner. Participants within each label group are then randomised to high information or low information condition, referring to the level of detail presented about the possible management options.

Aug 3, 2024 | onlinelibrary.wiley.com | Kathleen McFadden |Brooke Nickel |Nicole M. Rankin |Chloe J Jennett

1 INTRODUCTION Globally, lung cancer is the leading cause of cancer mortality.1 This is generally attributed to advanced-stage diagnoses, making earlier detection of lung cancer a worldwide priority for cancer control.

Jul 21, 2024 | insightplus.mja.com.au | Brooke Nickel

The way women are screened for breast cancer in Australia may change. There’s international debate on the age women should be invited for screening. But an even larger change being considered worldwide is whether to screen women at high and low risk of breast cancer differently. But what such a “risk-based” approach to screening might look like in Australia is not yet clear.

Sep 14, 2023 | paperity.org | Brooke Nickel |Kirsten J McCaffery |Jesse Jansen |Alexandra Barratt

PLOS ONE, Jul 2023 Management of low-risk ductal carcinoma in situ (DCIS) is controversial, with clinical trials currently assessing the safety of active monitoring amidst concern about overtreatment. Little is known about general community views regarding DCIS and its management. We aimed to explore women’s understanding and views about low-risk DCIS and current and potential future management options.

Jul 21, 2023 | journals.plos.org | Brooke Nickel |Kirsten J McCaffery |Jesse Jansen |Alexandra Barratt

Loading metrics Open Access Peer-reviewedResearch Article AbstractManagement of low-risk ductal carcinoma in situ (DCIS) is controversial, with clinical trials currently assessing the safety of active monitoring amidst concern about overtreatment. Little is known about general community views regarding DCIS and its management. We aimed to explore women’s understanding and views about low-risk DCIS and current and potential future management options.